What is HC Wainwright’s Estimate for TRVI FY2024 Earnings?

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – HC Wainwright decreased their FY2024 EPS estimates for Trevi Therapeutics in a report issued on Wednesday, December 4th. HC Wainwright analyst O. Livnat now anticipates that the company will post earnings per share of ($0.49) for the year, down from their prior forecast of ($0.47). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.49) per share. HC Wainwright also issued estimates for Trevi Therapeutics’ Q1 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.40) EPS, FY2026 earnings at ($0.55) EPS, FY2027 earnings at ($0.49) EPS and FY2028 earnings at ($0.38) EPS.

A number of other brokerages have also issued reports on TRVI. Leerink Partnrs upgraded Trevi Therapeutics to a “strong-buy” rating in a research report on Monday, September 9th. EF Hutton Acquisition Co. I raised shares of Trevi Therapeutics to a “strong-buy” rating in a research report on Monday, August 19th. Leerink Partners assumed coverage on shares of Trevi Therapeutics in a research report on Monday, September 9th. They issued an “outperform” rating and a $7.00 price target for the company. D. Boral Capital reaffirmed a “buy” rating and issued a $21.00 target price on shares of Trevi Therapeutics in a research report on Wednesday, December 4th. Finally, Needham & Company LLC restated a “buy” rating and set a $8.00 target price on shares of Trevi Therapeutics in a report on Wednesday, December 4th. Eight investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $9.13.

Trevi Therapeutics Stock Down 3.6 %

Shares of NASDAQ:TRVI opened at $2.66 on Monday. The firm has a 50-day simple moving average of $2.98 and a 200 day simple moving average of $2.91. Trevi Therapeutics has a fifty-two week low of $1.10 and a fifty-two week high of $4.00. The company has a market cap of $204.46 million, a PE ratio of -6.05 and a beta of 0.96.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). During the same period last year, the business posted ($0.08) earnings per share.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in TRVI. BNP Paribas Financial Markets boosted its holdings in Trevi Therapeutics by 130.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock worth $40,000 after buying an additional 6,764 shares during the period. American Century Companies Inc. raised its holdings in Trevi Therapeutics by 17.1% during the 2nd quarter. American Century Companies Inc. now owns 54,108 shares of the company’s stock valued at $161,000 after buying an additional 7,902 shares during the period. MAI Capital Management lifted its position in Trevi Therapeutics by 0.7% in the third quarter. MAI Capital Management now owns 1,327,285 shares of the company’s stock worth $4,433,000 after buying an additional 8,789 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in Trevi Therapeutics by 87.6% during the second quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company’s stock worth $73,000 after buying an additional 11,450 shares during the period. Finally, Price T Rowe Associates Inc. MD bought a new position in Trevi Therapeutics during the first quarter valued at $47,000. 95.76% of the stock is owned by institutional investors and hedge funds.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.